Global Parkinson's Disease Drugs Market to Reach $10 Billion by 2030
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, May 16, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Parkinson’s Disease Drugs Industry" - https://www.reportlinker.com/p06032440/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Parkinson’s Disease Drugs Market to Reach $10 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Parkinson’s Disease Drugs estimated at US$6 Billion in the year 2022, is projected to reach a revised size of US$10 Billion by 2030, growing at aCAGR of 6.6% over the period 2022-2030. Oral, one of the segments analyzed in the report, is projected to record 7.6% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Injection segment is readjusted to a revised 6.3% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 11.9% CAGR
The Parkinson’s Disease Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.
Select Competitors (Total 43 Featured)
- AbbVie Inc.
- ACADIA Pharmaceuticals
- Boehringer Ingelheim GmbH
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Impax Laboratories Inc.
- M Somerset Pharmaceuticals Inc.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Orion Pharma
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd
- Vertical Pharmaceuticals
Read the full report: https://www.reportlinker.com/p06032440/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Parkinson?s Disease Drugs - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Parkinson?s Disease Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Parkinson?s Disease
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Oral
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 5: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Injection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Injection by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Injection by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Transdermal by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Transdermal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 12: World 16-Year Perspective for Transdermal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Dopamine Agonists by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Dopamine Agonists by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Dopamine Agonists by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Parkinson?s Disease Drugs Market Analysis of
Annual Sales in US$ Million for Years 2014 through 2030
Table 17: World Recent Past, Current & Future Analysis for
Retail Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 19: World 16-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Online by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Online by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 22: World 16-Year Perspective for Online by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 23: World Recent Past, Current & Future Analysis for
Hospital Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 24: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 25: World 16-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 26: World Recent Past, Current & Future Analysis for MAO
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 27: World Historic Review for MAO Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 28: World 16-Year Perspective for MAO Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 29: World Recent Past, Current & Future Analysis for AChE
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 30: World Historic Review for AChE Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 31: World 16-Year Perspective for AChE Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 32: World Recent Past, Current & Future Analysis for
Glutamate Inhibitors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 33: World Historic Review for Glutamate Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 34: World 16-Year Perspective for Glutamate Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 35: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 36: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 37: World 16-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 38: USA Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: USA Historic Review for Parkinson?s Disease Drugs by
Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 40: USA 16-Year Perspective for Parkinson?s Disease Drugs
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injection and Transdermal for the Years 2014,
2023 & 2030
Table 41: USA Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 42: USA Historic Review for Parkinson?s Disease Drugs by
Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 43: USA 16-Year Perspective for Parkinson?s Disease Drugs
by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 44: USA Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 45: USA Historic Review for Parkinson?s Disease Drugs by
Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 46: USA 16-Year Perspective for Parkinson?s Disease Drugs
by Distribution Channel - Percentage Breakdown of Value Sales
for Retail Pharmacy, Online and Hospital Pharmacy for the Years
2014, 2023 & 2030
CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: Canada Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 49: Canada 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 50: Canada Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 51: Canada Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 52: Canada 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 53: Canada Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 54: Canada Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 55: Canada 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
JAPAN
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 56: Japan Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: Japan Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 58: Japan 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 59: Japan Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 60: Japan Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 61: Japan 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 62: Japan Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 63: Japan Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 64: Japan 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
CHINA
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 65: China Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 66: China Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 67: China 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 68: China Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 69: China Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 70: China 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 71: China Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 72: China Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 73: China 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
EUROPE
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 74: Europe Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 75: Europe Historic Review for Parkinson?s Disease Drugs
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR
Table 76: Europe 16-Year Perspective for Parkinson?s Disease
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2014, 2023 & 2030
Table 77: Europe Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: Europe Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 79: Europe 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 80: Europe Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 81: Europe Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 82: Europe 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 83: Europe Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 84: Europe Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 85: Europe 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
FRANCE
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 86: France Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: France Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 88: France 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 89: France Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 90: France Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 91: France 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 92: France Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 93: France Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 94: France 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
GERMANY
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 95: Germany Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Germany Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 97: Germany 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 98: Germany Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 99: Germany Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 100: Germany 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 101: Germany Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 102: Germany Historic Review for Parkinson?s Disease
Drugs by Distribution Channel - Retail Pharmacy, Online and
Hospital Pharmacy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 103: Germany 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
ITALY
Table 104: Italy Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: Italy Historic Review for Parkinson?s Disease Drugs
by Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 106: Italy 16-Year Perspective for Parkinson?s Disease
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injection and Transdermal for the Years
2014, 2023 & 2030
Table 107: Italy Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 108: Italy Historic Review for Parkinson?s Disease Drugs
by Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 109: Italy 16-Year Perspective for Parkinson?s Disease
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 110: Italy Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 111: Italy Historic Review for Parkinson?s Disease Drugs
by Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 112: Italy 16-Year Perspective for Parkinson?s Disease
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Retail Pharmacy, Online and Hospital Pharmacy for the
Years 2014, 2023 & 2030
UNITED KINGDOM
Parkinson?s Disease Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 113: UK Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: UK Historic Review for Parkinson?s Disease Drugs by
Route Of Administration - Oral, Injection and Transdermal
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 115: UK 16-Year Perspective for Parkinson?s Disease Drugs
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injection and Transdermal for the Years 2014,
2023 & 2030
Table 116: UK Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Drug Class - Dopamine Agonists,
MAO Inhibitors, AChE Inhibitors, Glutamate Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 117: UK Historic Review for Parkinson?s Disease Drugs by
Drug Class - Dopamine Agonists, MAO Inhibitors, AChE
Inhibitors, Glutamate Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 118: UK 16-Year Perspective for Parkinson?s Disease Drugs
by Drug Class - Percentage Breakdown of Value Sales for
Dopamine Agonists, MAO Inhibitors, AChE Inhibitors, Glutamate
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030
Table 119: UK Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Distribution Channel - Retail
Pharmacy, Online and Hospital Pharmacy - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR
Table 120: UK Historic Review for Parkinson?s Disease Drugs by
Distribution Channel - Retail Pharmacy, Online and Hospital
Pharmacy Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 121: UK 16-Year Perspective for Parkinson?s Disease Drugs
by Distribution Channel - Percentage Breakdown of Value Sales
for Retail Pharmacy, Online and Hospital Pharmacy for the Years
2014, 2023 & 2030
SPAIN
Table 122: Spain Recent Past, Current & Future Analysis for
Parkinson?s Disease Drugs by Route Of Administration - Oral,
Injection and Transdermal - Independent Analysis of Annual
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032440/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
